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Reply
Sir—We read with interest the letter by
Tattevin et al. [1] questioning the validity
of studies of candidemia epidemiology
conducted without the use of selective
blood culture bottles for fungus detection.
We fully agree that the detection of fun-
gemia—as performed in most institutions
today—is not optimal, and that the use of
special methods would certainly improve
both the time to and the rate of detection.
In vitro and in vivo studies have indeed
demonstrated an advantage of special me-
dia in favoring yeast growth (particularly
that of Candida glabrata) or inhibiting
concomitant bacteria in blood [2–5].
However, the systematic use of such media
is expensive. Their selective use for pa-
tients at risk for candidemia is attractive,
but this population is difficult to identify.
In our institution, the majority of cases of
fungemia were detected among patients
for whom there was no special request for
fungal blood cultures.
Tattevin et al. [1] claim that not using
special fungal blood culture media could
impede or delay the detection of some
non-albicans species of Candida, such as
C. glabrata. We have conducted a further
analysis of the data published in our 10-
year Swiss survey [6] to assess differences
in the proportions of Candida albicans and
non-albicans species of Candida (partic-
ularly C. glabrata) reported by the 7 lab-
oratories using special fungal media and
the 9 others using standard automated-
monitoring blood culture systems. No dif-
ference was observed between the 2 groups
of institutions nor in the ranking of Can-
dida species among the most frequent
bloodstream isolates. In addition, in one
of the major hospitals participating in our
study, use of special fungal blood culture
bottles was introduced mid-survey with-
out leading to a higher detection of non-
albicans species of Candida [7].
Time to detection, although very per-
tinent for patient management, has no in-
fluence on studies such as ours, which re-
quire only that the incubation time for
blood culture is long enough (5–7 days)
to allow the detection of almost all Can-
dida isolates from blood cultures. In this
type of study, the emphasis is on the num-
ber of cases of candidemia and not on the
number of bottles that yield an isolate nor
on the time to detection.
In this respect, it is interesting to note
that, as in our report, none of the can-
didemia studies mentioned in the letter by
Tattevin et al. [1] or referenced in our ar-
ticle [6] specify the type of blood culture
bottle or system used or the duration of
incubation. Moreover, even population-
based prospective surveillance studies such
as those of Kao et al. [8] and Trick et al.
[9] do not mention how candidemia ep-
isodes were diagnosed, beyond the basic
definition of 1 or more blood culture(s)
positive for Candida species.
Thus, within the imperfections and var-
iations in current laboratory practices, as
well as patient selection, studies of the ep-
idemiology of candidemia do offer useful
information and can be compared. Inter-
esting—and intriguing—differences in the
incidence of candidemia and the distri-
bution of Candida species are reported
within and between continents, which
should trigger further research regarding
their origin.
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Risk Factors for
Extrapulmonary Tuberculosis
Sir—We were surprised by the findings of
Yang et al. [1] suggesting that female sex
and non-Hispanic black race are risk fac-
